Politico, June 15, 2021: The controversial approval of the first drug to target Alzheimer’s disease in nearly 20 years has been blasted by many experts, because the drug is not proven to work and will cost $56,000 per year. “You don’t have to be a rocket scientist to know that the impact on Medicare is likely to be devastating,” said Diana Zuckerman, the president of the National Center for Health Research.
Read More »Tag: alzheimer’s disease
Statement of Dr. Diana Zuckerman on FDA’s Approval of Alzheimer’s Drug Aduhelm
June 8, 2021: Dr. Diana Zuckerman, president of NCHR, speaks out against FDA’s approval of the ineffective Alzheimer’s drug aduhelm.
Read More »NCHR Statement at FDA Alzheimer’s Advisory Committee Meeting On Aducanumab
November 6, 2020: Aducanumab could be promising, but we need better evidence before approving it.
Read More »Why isn’t there a cure for Alzheimer’s Disease or Dementia?
We reviewed a proposed 2015 controversial health law that would have had a terrible impact on the lives of Alzheimer’s patients and their families, who would have spent billions on medications that don’t work and can cause cancer.
Read More »Which Common Medications May Cause Dementia Symptoms?
You may have heard the media coverage that common medications may increase the risk for dementia. What do these drugs all have in common, what do you need to know about them, and are there really risks to taking them?
Read More »